Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

Cellosaurus Reh (CVCL_1650)

[Text version]
Cell line name Reh
Synonyms REH
Accession CVCL_1650
Resource Identification Initiative To cite this cell line use: Reh (RRID:CVCL_1650)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8286.
Doubling time: 34.7 hours (PubMed=8847894); 30 hours (PubMed=25984343); ~50-70 hours (DSMZ=ACC-22).
Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (PubMed=8704231; PubMed=9067587; PubMed=15843827; PubMed=35354797).
  • Mutation; HGNC; 7978; NR3C1; Simple; p.Gln527Ter (c.1579C>T) (p.Gln528Ter, c.1582C>T); Zygosity=Homozygous (PubMed=35124168).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (Cosmic-CLP=909696; DepMap=ACH-000960).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (Cosmic-CLP=909696; DepMap=ACH-000960).
HLA typing Source: DSMZCellDive=ACC-22
Class I
HLA-AA*23:01:01,32:01:01
HLA-BB*35:02:01,50:01:01
HLA-CC*04:01:01,06:02:01
Class II
HLA-DPDPA1*01:03:01,01:03:01
DPB1*04:02:01,04:01:01
HLA-DQDQA1*05:05:01,05:05:01
DQB1*03:01:01,03:01:01
HLA-DRDRA*01:02:02,01:02:02
DRB1*11:01:01,12:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African21.18
Native American0.09
East Asian, North1.57
East Asian, South2
South Asian1.52
European, North15.6
European, South58.04
Disease Childhood B acute lymphoblastic leukemia (NCIt: C9140)
B lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1) ETV6-RUNX1 (NCIt: C80334)
B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1) (ORDO: Orphanet_585929)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_8857 (EU-1)CVCL_0011 (KM-3)CVCL_8462 (NOI-90)
CVCL_ZV66 (Reh/EphA3)CVCL_A049 (WSU-CLL)
Sex of cell Female
Age at sampling 15Y
Category Cancer cell line
STR profile Source(s): AddexBio=C0003031/4985; ATCC=CRL-8286; CLS=300320; Cosmic-CLP=909696; DSMZ=ACC-22; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,11,12 (AddexBio=C0003031/4985; ATCC=CRL-8286; PubMed=25877200)
12,13 (CLS=300320; Cosmic-CLP=909696; DSMZ=ACC-22)
D2S133820,22
D3S135818
D5S81811,12 (Cosmic-CLP=909696; DSMZ=ACC-22)
11,12,13 (CLS=300320)
11,13 (AddexBio=C0003031/4985; ATCC=CRL-8286; PubMed=25877200)
D7S8209,10,12,13 (CLS=300320)
9,12 (AddexBio=C0003031/4985; ATCC=CRL-8286; Cosmic-CLP=909696; DSMZ=ACC-22; PubMed=25877200)
D8S117913,14,16,17 (CLS=300320)
13,15 (ATCC=CRL-8286; DSMZ=ACC-22; PubMed=25877200)
D13S31710,11,14 (DSMZ=ACC-22)
11,12,13 (CLS=300320)
11,13 (AddexBio=C0003031/4985; ATCC=CRL-8286; PubMed=25877200)
11,14 (Cosmic-CLP=909696)
D16S5399 (AddexBio=C0003031/4985; ATCC=CRL-8286; PubMed=25877200)
9,10,12,13 (CLS=300320)
9,13 (Cosmic-CLP=909696; DSMZ=ACC-22)
D18S5110,11,14 (CLS=300320)
10,14 (ATCC=CRL-8286; PubMed=25877200)
10,14,15 (DSMZ=ACC-22)
D19S43312,14
D21S1127,28,30,31 (DSMZ=ACC-22)
28,29,30,31 (CLS=300320)
28,30 (ATCC=CRL-8286; PubMed=25877200)
FGA13,22,23 (DSMZ=ACC-22)
22,23 (ATCC=CRL-8286; PubMed=25877200)
22,23,24 (CLS=300320)
Penta D9,11 (ATCC=CRL-8286; PubMed=25877200)
9,12 (CLS=300320)
10,11 (DSMZ=ACC-22)
Penta E7,11 (ATCC=CRL-8286; DSMZ=ACC-22; PubMed=25877200)
10,11 (CLS=300320)
TH017 (AddexBio=C0003031/4985; ATCC=CRL-8286; CLS=300320; PubMed=25877200)
7,9 (Cosmic-CLP=909696; DSMZ=ACC-22)
TPOX8
vWA14,15 (AddexBio=C0003031/4985; ATCC=CRL-8286; Cosmic-CLP=909696; PubMed=25877200)
14,15,16 (CLS=300320; DSMZ=ACC-22)

Run an STR similarity search on this cell line
Web pages https://www.proteinatlas.org/learn/cellines
https://tcpaportal.org/mclp/
Publications

PubMed=194778; DOI=10.1016/0014-2964(77)90085-8
Rosenfeld C., Goutner A., Venuat A.-M., Choquet C., Pico J.-L., Dore J.-F., Liabeuf A., Durandy A., Desgrange C., de The G.B.
An effect human leukaemic cell line: Reh.
Eur. J. Cancer 13:377-379(1977)

PubMed=197411; DOI=10.1038/267841a0
Rosenfeld C., Goutner A., Choquet C., Venuat A.-M., Kayibanda B., Pico J.-L., Greaves M.F.
Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line.
Nature 267:841-843(1977)

DOI=10.1007/BF00204739
Bertoglio J., Guibout C., Dore J.-F., Rosenfeld C.
Further characterization of a non-T, non-B acute lymphoblastic leukaemia cell line (Reh). Reactivity with human sera cytotoxic for leukaemia cells.
Cancer Immunol. Immunother. 4:193-196(1978)

PubMed=279400
Lorans G., Rosenfeld C., Petitou M., Phan-Dinh-Tuy F., Mathe G.
Metabolism of proline in a human leukemic lymphoblastoid cell line.
Cancer Res. 38:3950-3953(1978)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3866637
Sharif A., Driancourt C., Billard M., Rosenfeld C., Goussault Y., Bourrillon R.
In vitro study of the comparative behaviour of a human acute lymphoblastic leukemia cell line and a reference normal cell line towards the effects of a mitogenic lectin.
Cancer Biochem. Biophys. 8:143-152(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=7630190
Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)

PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608
Zhou M.-X., Yeager A.M., Smith S.D., Findley H.W.
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Blood 85:1608-1614(1995)

PubMed=8704231; DOI=10.1182/blood.V88.3.785.785
Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y., Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D., Smith S.D.
TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines.
Blood 88:785-794(1996)

PubMed=8847894
Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Leukemia 10:1592-1603(1996)

PubMed=9067587; DOI=10.1038/sj.leu.2400571
Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A., Janssen J.W.G., Drexler H.G.
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Leukemia 11:441-447(1997)

PubMed=9108419; DOI=10.1182/blood.V89.8.2986
Findley H.W., Gu L.-B., Yeager A.M., Zhou M.-X.
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Blood 89:2986-2993(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2
Matsuo Y., Drexler H.G.
Establishment and characterization of human B cell precursor-leukemia cell lines.
Leuk. Res. 22:567-579(1998)

PubMed=9823951; DOI=10.1038/sj.leu.2401198
Zhou M.-X., Gu L.-B., Yeager A.M., Findley H.W.
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Leukemia 12:1756-1763(1998)

PubMed=10490826; DOI=10.1038/sj.onc.1202874
Fu X.-Y., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.
EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1.
Oncogene 18:4920-4929(1999)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=16523483; DOI=10.1002/gcc.20317
Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Dexter T.J., Ashworth A., Kearney L.
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Genes Chromosomes Cancer 45:554-564(2006)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20575032; DOI=10.1002/ajh.21738
Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I., Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i., Tada M., Moriuchi T., Sugita K.
A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.
Am. J. Hematol. 85:535-537(2010)

PubMed=21552520; DOI=10.1371/journal.pone.0019169
Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A., Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P., Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.
Survey of activated FLT3 signaling in leukemia.
PLoS ONE 6:E19169-E19169(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24056532; DOI=10.1101/gr.159913.113
Potter N.E., Ermini L., Papaemmanuil E., Cazzaniga G., Vijayaraghavan G., Titley I., Ford A., Campbell P.J., Kearney L., Greaves M.F.
Single-cell mutational profiling and clonal phylogeny in cancer.
Genome Res. 23:2115-2125(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27922598; DOI=10.1038/leu.2016.371
Charmsaz S., Al-Ejeh F., Yeadon T.M., Miller K.J., Smith F.M., Stringer B.W., Moore A.S., Lee F.-T., Cooper L.T., Stylianou C., Yarranton G.T., Woronicz J., Scott A.M., Lackmann M., Boyd A.W.
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
Leukemia 31:1779-1787(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28569787; DOI=10.1038/cddis.2017.249
Kasai S., Furuichi Y., Ando N., Kagami K., Abe M., Nakane T., Goi K., Inukai T., Saitoh S., Ohno S., Okazaki S., Nagano O., Saya H., Sugita K.
Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression.
Cell Death Dis. 8:e2857.1-e2857.11(2017)

PubMed=29786757; DOI=10.1007/s12185-018-2474-7
Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H., Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T., Sugita K., Hosoi H.
Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
Int. J. Hematol. 108:312-318(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068
Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C., Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H., Minegishi M., Iwamoto S., Sugita K., Inukai T.
Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022)

PubMed=35354797; DOI=10.1038/s41467-022-29224-5
Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T., Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E., Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I., Lehtio J., Vesterlund M., Jafari R.
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.
Nat. Commun. 13:1691.1-1691.19(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0003031/4985
ATCC; CRL-8286
BCRJ; 0321
CLS; 300320
DSMZ; ACC-22
Cell line databases/resources CLO; CLO_0008781
CLO; CLO_0008782
CLDB; cl4132
cancercelllines; CVCL_1650
CCRID; 3101HUMTCHu131
Cell_Model_Passport; SIDM00447
Cosmic-CLP; 909696
DepMap; ACH-000960
DSMZCellDive; ACC-22
LINCS_LDP; LCL-1039
Lonza; 58
Anatomy/cell type resources BTO; BTO:0001163
Biological sample resources BioSample; SAMN03471040
BioSample; SAMN03473380
BioSample; SAMN10988185
CRISP screens repositories BioGRID_ORCS_Cell_line; 1761
Chemistry resources ChEMBL-Cells; CHEMBL3308823
ChEMBL-Targets; CHEMBL2366320
GDSC; 909696
PharmacoDB; REH_1299_2019
PubChem_Cell_line; CVCL_1650
Encyclopedic resources Wikidata; Q29958043
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM236802
GEO; GSM236838
GEO; GSM482492
GEO; GSM499514
GEO; GSM499538
GEO; GSM499727
GEO; GSM499733
GEO; GSM887530
GEO; GSM888612
GEO; GSM931330
GEO; GSM931331
GEO; GSM1195448
GEO; GSM1374847
GEO; GSM1670369
GEO; GSM2373798
GEO; GSM2373799
GEO; GSM5137740
GEO; GSM5137741
Polymorphism and mutation databases Cosmic; 798668
Cosmic; 801720
Cosmic; 909696
Cosmic; 919149
Cosmic; 991551
Cosmic; 994183
Cosmic; 996287
Cosmic; 998706
Cosmic; 999751
Cosmic; 1012114
Cosmic; 1037725
Cosmic; 1067440
Cosmic; 1093790
Cosmic; 1118468
Cosmic; 1130244
Cosmic; 1191700
Cosmic; 1483360
Cosmic; 1524815
Cosmic; 2491075
Cosmic; 2523595
Cosmic; 2649233
IARC_TP53; 21284
IARC_TP53; 28432
LiGeA; CCLE_618
Progenetix; CVCL_1650
Proteomic databases PRIDE; PXD023662
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number45